HNSA 5487
Alternative Names: HNSA-5487Latest Information Update: 02 May 2025
At a glance
- Originator Hansa Biopharma AB
- Class Antineoplastics; Enzymes
- Mechanism of Action Immunoglobulin G degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Cancer
Most Recent Events
- 21 Mar 2025 Hansa Biopharma AB plans to align with regulatory authorities on a clinical development path for HNSA 5487 in Myasthenia gravis in the first half of 2025
- 07 Oct 2024 Efficacy and immunogenicity data from the phase I NICE-01 trial in Autoimmune disorders and Cancer (In volunteers) released by Hansa Biopharma
- 07 Oct 2024 Hansa Biopharma plans a clinical trials for Myelin oligodendrocyte glycoprotein antibody disease, Neuromyelitis optica and Myasthenia gravis